뇌질환의 혁신, 뉴로벤티(NeuroVenti)

SCIENCE & TECHNOLOGY

Vision for the Future

We will grow into a world-class company in the field of
developing treatments for intractable brain diseases.

Candidate Indication Preclinical Clinical IP Remarks
NV01-A02 Autism spectrum disorder
Proceeding
KR, PCT, USA, EU, China, Japan * Preparing for phase 2 clinical trial in Korea
Fragile X syndrome
Proceeding
KR, PCT, USA, EU, China, Japan * Preparing for phase 2 overseas clinical trials
NV01-A03 Autism spectrum disorder
Proceeding
KR, PCT, USA, EU, China, Japan * Preparing for phase 2 overseas clinical trials
NV01-062 Autism spectrum disorder
Proceeding
KR, PCT  
NV01-E01 Autism spectrum disorder
Proceeding
* Exploratory clinical trials in progress

NV01-A02

- Precision multi-targets
- Non-clinical testing completed
- Preparation for domestic and global phase II clinical trials (Pre-IND meeting)
- Approved by the US FDA as ODD (Oct 24, 2022)

NV01-A02

NV01-A03

- Drug repurposing strategy
- Non-clinical testing completed
- Global Clinical Trial Preparation (EMA Scientific Advice)

NV01-A03

NV01-062

- NCE
- Multiple new targets
- Non-clinical efficacy test completed aginst ASD
- PK and non-clinical toxycity test is ongoing

NV01-062

NV01-E01

- Electroceutical
- In the progress of exploratory clinical trials (Nueyne joint development)
- Developing a combined administration protocol of our chemical drug and electroceuticals
- Conducting joint research with Korean key opinion leaders in the treatment of neurodevelopmental disorders

NV01-e01